Safety and Efficacy of Sotorasib in KRAS-Mutated Pancreatic Cancer
Posted: 01/13/2023 | By: Kayci Reyer

CodeBreak 100 is a single-group, phase I/II trial aiming to assess the safety and efficacy of sotorasib treatment in pretreated patients with KRAS G12C–mutated pancreatic cancer. Results from the study were recently published by Strickler et al in The New England Journal of Medicine.

Question 1 of 5

What approximate percentage of pancreatic cancers harbor a KRAS G12C mutation?

Choose 1